Showing results (111-120 of 194) with videos related to
Sort By:
Pageof 20
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.Infectious Diseases of Poverty|December 6, 2017
Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countriesRichard M Gibson, Gabrielle Nickel, Michael Crawford, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 6, 2010
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoringFred Lyagoba, David T Dunn, Deenan Pillay, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 28, 2017
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan AfricaCissy Kityo, Jennifer Thompson, Immaculate Nankya, et al.AIDS (London, England)|August 8, 2013
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling studyBrooke E Nichols, Kim C E Sigaloff, Cissy Kityo, et al.International Health|January 13, 2018
Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and UgandaGeorge Abongomera, Levison Chiwaula, Paul Revill, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 TrialsChloe Orkin, Faiza Ajana, Cissy Kityo, et al.International Health|March 25, 2017
Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveysGeorge Abongomera, Sylvia Kiwuwa-Muyingo, Paul Revill, et al.The New England Journal of Medicine|July 21, 2021
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNicholas I Paton, Joseph Musaazi, Cissy Kityo, et al.The Journal of Infectious Diseases|March 27, 2012
Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan AfricaKim C E Sigaloff, Raph L Hamers, Carole L Wallis, et al.Pageof 20